Dry eye disease treatment with Xiidra® (lifitegrast ophthalmic solution) 5% | ECP
IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

A proven treatment,
in your hands

Explore the Xiidra® clinical data to see if it is the right treatment for your
patients with dry eye disease.

sticky line
Ken Jeong holding Xiidra
sticky line

A proven
treatment,
in your hands

Explore the Xiidra® clinical data to see if it is the right treatment for your patients with dry eye disease.

Dry eye scale
Dry eye scale

Symptoms

Xiidra & symptoms of
dry eye disease

The effect of Xiidra on the symptoms of dry eye disease was evaluated in 4 robust clinical studies.1

Explore the data

Inferior fluorescein Corneal Staining Score (ICSS)

Inferior fluorescein Corneal Staining Score (ICSS) from 0 to 4

Signs

Xiidra & dry eye disease signs

The impact of Xiidra on the signs of dry eye disease was measured in 4 robust clinical studies.1

See the results
Inferior fluorescein Corneal Staining Score (ICSS) from 0 to 4

Safety

Xiidra safety data in clinical trails

The adverse reactions of Xiidra were studied across 5 clinical trials in patients with dry eye disease.1

Review the data
Xiidra tolerability chart

Safety

Xiidra safety data in clinical trails

The adverse reactions of Xiidra were studied across 5 clinical trials in patients with dry eye disease.1

Review the data

†In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. 170 patients were exposed to Xiidra for approximately 12 months.1

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.